These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 10765944)

  • 1. Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays.
    Russell E; Zeihen M; Wergin S; Litton T
    Arthritis Rheum; 2000 Apr; 43(4):944. PubMed ID: 10765944
    [No Abstract]   [Full Text] [Related]  

  • 2. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?
    Yazici Y; Erkan D
    Ann Rheum Dis; 2004 May; 63(5):607-8; author reply 608. PubMed ID: 15082503
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis.
    Blank N; Max R; Schiller M; Briem S; Lorenz HM
    Rheumatology (Oxford); 2009 Apr; 48(4):440-1. PubMed ID: 19153143
    [No Abstract]   [Full Text] [Related]  

  • 4. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy.
    Gómez-Puerta JA; Sanmartí R; Rodríguez-Cros JR; Cañete JD
    Ann Rheum Dis; 2004 Jul; 63(7):896. PubMed ID: 15194598
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
    Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of cold agglutinin disease in RA patient during etanercept therapy successfully treated with rituximab.
    Malesci D; La Montagna G
    Rheumatology (Oxford); 2008 May; 47(5):734-5. PubMed ID: 18326535
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
    Wallenius M; Rødevand E; Skomsvoll JF
    Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1664-6. PubMed ID: 15976836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic agents for rheumatoid arthritis: infliximab (a chimeric human IgG 1 monoclonal antibody to TNF-alpha) and etanercept (a soluble form of human TNF type II receptor linked to an IgG 1-Fc moietry)].
    Akiyama Y; Mimura T
    Masui; 2006 Jul; 55(7):864-72. PubMed ID: 16856547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept and infliximab for rheumatoid arthritis.
    Drug Ther Bull; 2001 Jul; 39(7):49-52. PubMed ID: 11471515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
    Ang HT; Helfgott S
    J Rheumatol; 2003 Nov; 30(11):2315-8. PubMed ID: 14677170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract]   [Full Text] [Related]  

  • 13. Anaphylactic reaction in a patient with rheumatoid arthritis: a rare side effect of methotrexate with etanercept as a provoking factor?
    Houtman PM; Jansen TL; Blanken R
    J Clin Rheumatol; 2006 Dec; 12(6):321-2. PubMed ID: 17149070
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor necrosis factor inactivation in the management of rheumatoid arthritis.
    Baumgartner SW
    South Med J; 2000 Aug; 93(8):753-9. PubMed ID: 10963503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A new treatment for rheumatoid arthritis].
    Vervaeren J
    J Pharm Belg; 2002; 57(4):82-8. PubMed ID: 12357696
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of rheumatoid arthritis with a tumor necrosis factor receptor-Fc fusion protein.
    Mannik M; Wener M
    N Engl J Med; 1997 Nov; 337(21):1560; author reply 1560-1. PubMed ID: 9380131
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of tumor necrosis factor inhibitors in patients with RA.
    Trethewey P
    JAAPA; 2002 Sep; 15(9):23-4, 27, 30 passim. PubMed ID: 12395668
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.
    Kekow J; Welte T; Kellner U; Pap T
    Arthritis Rheum; 2002 Mar; 46(3):843-4. PubMed ID: 11920425
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.